Study of two drugs for leukemia with TP53 mutation
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests combining two drugs, ropeginterferon alfa-2b and azacitidine, for people with myelodysplastic syndrome or acute myeloid leukemia that has a TP53 gene change. The treatment may help control the cancer, and the study includes people who are newly diagnosed or whose disease has not responded to prior therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have MDS or AML with a TP53 gene change (detected by a blood or bone marrow test).
- You are 18 years or older.
- For the newly diagnosed group, you are unable to receive intensive chemotherapy because of age (60 or older) or other health issues, and you have at least 10% blasts in your bone marrow or blood.
- Your liver function is within acceptable limits (certain blood tests).
- You are not pregnant, and you agree to use effective contraception during the study and for at least 4 months after treatment ends.
- If you have hepatitis B, C, or HIV, your viral load must be undetectable or treated adequately.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called APG1252 combined with azacitidine (AZA) for people with high-risk AML or certain related blood cancers. The goal is to see if the combination works better than standard treatments.
This trial tests a combination treatment (chemo drugs plus a growth-factor medicine) for people newly diagnosed with acute myeloid leukemia (AML) or certain high-risk myelodysplastic syndromes (MDS). It may help by targeting cancer cells in the blood and bone marrow and improving remission chances.
This trial tests a combination of three medicines—azacitidine, venetoclax, and gilteritinib—in people with specific gene changes (FLT3 mutations) in leukemia and related bone marrow diseases that have come back or are hard to treat. The goal is to see if this drug combination can control the disease and improve outcomes.
This trial tests a new drug, rezatapopt, combined with azacitidine for people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has come back or not responded to treatment. It is only for people whose cancer cells have a specific change in a gene called TP53 (the Y220C mutation). The goal is to see if this combination can help control the disease.
This study tests a medication called ropeginterferon alfa-2b for people with certain blood cancers that have features of both myelodysplastic syndromes and myeloproliferative neoplasms. The drug may help control blood counts and reduce symptoms.
This trial tests a new drug (axatilimab) combined with two standard chemotherapy drugs (decitabine and venetoclax) for people with acute myeloid leukemia (AML) that has a TP53 mutation. The goal is to see if this combination helps control the cancer better than current treatments.
Hear when a new Ropeginterferon trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.